Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma

New England Journal of Medicine

Volumn 338, Issue 18, 1998, Pages 1272-1278

  Negrier, Sylvie ^a   Escudier, Bernard ^b   Lasset, Christine ^a   Douillard, Jean Yves ^c   Savary, Jacqueline ^a   Chevreau, Christine ^d   Ravaud, Alain ^e   Mercatello, Alain ^f   Peny, Jean ^g   Mousseau, Mireille ^h   Philip, Thierry ^a   Tursz, Thomas ^b  

^a CENTRE LÉON BÉRARD   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e INSTITUT BERGONIÉ   (France)

^f EDOUARD HERRIOT HOSPITAL   (France)

^g CENTRE FRANÇOIS BACLESSE   (France)

^h HÔPITAL MICHALLON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; HYPERBILIRUBINEMIA; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; WEIGHT REDUCTION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERFERON ALFA-2A; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 7144227930     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199804303381805     Document Type: Article

References (23)

1. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988; 48:7310-3.
2. Dekernion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 1978;120:148-52.
3. Philip T, Négrier S, Lasset C, et al. Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines: analysis of a single institution study on 181 patients. Br J Cancer 1993;68:1036-42.
4. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75.
5. Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-α. Eur J Cancer 1994;30A:1310-4.
6. Palmer PA, Vinke J, Philip T, et al. Prognostic factors for survival in patients with advanced renai cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992;3:475-80.
7. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-92.
8. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activatcd killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-97.
9. West WH, Tauer KW, Yannelli JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898-905.
10. Atzpodien J, Korfer A, Franks CR, Poliwoda H, Kirchner H. Home therapy with recombinant interleukin-2 and interferon-α 2b in advanced human malignancies. Lancet 1990;335:1509-12.
11. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993;20:283-95.
12. Wang JCL, Walle A, Novogrodsky A, et al. A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogenactivated autologous leukocytes and continuous infusion interleukin-2. J Clin Oncol 1989;7:1885-91.
13. Dillman RO, Oldham RK, Tauer KW, et al. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. J Clin Oncol 1991;9:1233-40.
14. Fisher RI, Coltman CA Jr, Doroshow JH, et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells: a phase II clinical trial. Ann Intern Med 1988;108:518-23.
15. Parkinson DR, Fisher RI, Rayner AA, et al. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J Clin Oncol 1990;8:1630-6.
16. Négrier S, Philip T, Stoter G, et al. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. Eur J Cancer Clin Oncol 1989;25:Suppl 3:S21-S28.
17. Pockaj BA, Topalian SL, Steinberg SM, White DE, Rosenberg SA. Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses. J Clin Oncol 1993;11:136-47.
18. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
19. Thiesse P, Ollivier L, Di Stefano-Louineau D, et al. Response rate accuracy in oncology trials: reasons for interobserver variability. J Clin Oncol 1997;15:3507-14.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
21. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
22. Oliver RTD. Renal cell cancer: is there long-term survival advantage from cytokine treatment? Eur J Cancer 1994;30A:1214-6.
23. Jones M, Philip T, Palmer P, et al. The impact of interleukin 2 on survival in renal cancer: a multivariate analysis. Cancer Biother 1993;8:275-88.